# CD53 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CD53 is a leukocyte-restricted tetraspanin protein crucial for immune cell signaling, adhesion, and migration, orchestrating these functions by organizing protein complexes within tetraspanin-enriched microdomains (TEMs). Its gene is located on human chromosome 1p13.3, a region associated with immune disorders and hematopoietic malignancies.

- The CD53 gene structure features 8 exons and 7 introns, with its promoter lacking a TATA box but containing GC-rich regions and binding sites for key transcription factors like PU.1, ETS-1, and EBF1, dictating its restricted expression in lymphoid and myeloid lineages. Minor alternatively spliced isoforms, including one lacking the EC2 domain, may modulate tetraspanin complex assembly.

- CD53 plays critical roles in B-cell development by stabilizing the IL-7 receptor and promoting HSC quiescence by facilitating the DREAM complex assembly in response to inflammatory stimuli, thereby protecting stem cells from exhaustion. It also regulates lymphocyte trafficking by stabilizing L-selectin and modulates integrin-mediated migration.

- Genetic variants in CD53 have been linked to disease susceptibility and therapeutic outcomes, including improved survival after bone marrow transplantation and increased susceptibility to tuberculosis. Somatic mutations in CD53 are rare but observed in cancers like lung adenocarcinoma and AML, often predicted to impair protein function.

- CD53 is implicated in host-pathogen interactions, notably facilitating HTLV-1 envelope glycoprotein-mediated cell fusion by clustering its receptor, GLUT1, and potentially influencing the immune response to *Mycobacterium tuberculosis*. Its expression is also dysregulated in various cancers (LUAD, TNBC, AML) and non-cancer diseases (atherosclerosis, diabetic kidney disease), serving as a potential diagnostic and prognostic biomarker.

- Therapeutic strategies targeting CD53 are under preclinical development, including monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers, and CAR-T cells, primarily for hematological malignancies like AML, leveraging its surface expression and restricted leukocyte tropism.

---

## Executive Summary & Key Metadata

CD53 (Cluster of Differentiation 53), also known as TSPAN25 or MOX44, is a member of the tetraspanin transmembrane 4 superfamily (TM4SF). It is a leukocyte-restricted surface glycoprotein with four transmembrane domains that orchestrates membrane organization, signal transduction, and cell migration. The gene is located on human chromosome 1p13.3, a region frequently implicated in hematopoietic malignancies and immune disorders. CD53 is expressed predominantly on cells of the lymphoid-myeloid lineage, including B cells, T cells, natural killer (NK) cells, dendritic cells, monocytes, macrophages, and megakaryocytes, where it modulates receptor clustering, intracellular signaling, and cytoskeletal dynamics [1, 2, 5, 22].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CD53 |
| UniProt Accession | P19397 |
| Representative PDB ID | true (structural models available via homology; see Section 2) |
| Chromosomal Locus | 1p13.3 (human); mouse chromosome 3 [5, 13] |
| Primary Molecular Function | Tetraspanin membrane scaffold; regulation of immune cell signaling, adhesion, migration, and receptor stabilization |
| Disease & Pathology Associations | Hematopoietic malignancies (AML, multiple myeloma, lymphoma), lung adenocarcinoma, breast cancer metastasis, atherosclerosis, tuberculosis susceptibility, diabetic kidney disease, autoimmune disorders, and transplant outcomes [1, 7, 8, 10, 11, 15, 17, 26, 64, 65, 66, 67, 69, 70, 74] |

CD53 functions as a molecular facilitator, organizing partner proteins into membrane microdomains (tetraspanin-enriched microdomains, TEMs) that amplify or dampen signaling cascades. Its clinical relevance spans from hematopoietic stem cell (HSC) quiescence and B-cell development to cancer progression and host-pathogen interactions. This manual provides a comprehensive, biophysically rigorous analysis of CD53, integrating genomic, structural, proteomic, and clinical data.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human CD53 gene was first mapped to chromosomal region 1p13 by González et al. (1993) using somatic cell hybrids and in situ hybridization [5]. This localization was independently confirmed by Taguchi et al. (1993), who mapped the gene to 1p13 in humans and to conserved syntenic regions in mouse (chromosome 3) and rat [13]. The 1p13 region is gene-dense and contains multiple immune-related loci, including the CD58 gene and members of the immunoglobulin superfamily. A HindIII restriction fragment length polymorphism (RFLP) within the CD53 locus was identified by Gallego et al. (1994), providing an early genetic marker for linkage studies [6].

The genomic structure of the human CD53 gene was characterized by Kořínek and Hořejší (2004) [3]. The gene spans approximately 12 kilobases (kb) and consists of 8 exons and 7 introns. The exon-intron boundaries are conserved with other tetraspanin family members, supporting the hypothesis that TM4SF genes arose via ancient duplication events [12, 14]. The coding sequence is distributed across exons 2–8, with exon 1 containing the 5' untranslated region (UTR) and the translation initiation codon. The 3' UTR, located in exon 8, contains multiple AU-rich elements (AREs) that regulate mRNA stability in response to inflammatory stimuli.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of CD53 lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites, a feature common to housekeeping and immune-regulated genes. Hernández-Torres et al. (2001) performed a detailed functional dissection of the 5' flanking region and identified two critical regulatory modules: a proximal promoter element spanning nucleotides -200 to -50 relative to the transcription start site (TSS), and a distal enhancer element located between -1,800 and -1,200 [2]. The proximal element contains binding sites for the ETS family transcription factors (e.g., PU.1, ETS-1) and C/EBP, which are essential for myeloid and lymphoid expression. The distal enhancer harbors a functional binding site for early B-cell factor 1 (EBF1), a master regulator of B-cell commitment [21].

Importantly, the CD53 promoter is arranged in a head-to-head (bidirectional) configuration with a second gene of unknown function, oriented in the opposite transcriptional direction. Hernández-Torres et al. demonstrated that the intergenic region contains a shared promoter-enhancer element that drives expression of both genes, but the two genes are differentially regulated: CD53 expression is restricted to leukocytes, while the opposite-strand gene is ubiquitously expressed [2]. This bidirectional architecture imposes constraints on chromatin remodeling and may explain the tight lineage-specific regulation of CD53.

### 1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation (ChIP) studies and promoter-reporter assays have identified the following transcription factor binding sites in the CD53 regulatory regions:

| **Transcription Factor** | **Binding Location** | **Functional Role** |
|---|---|---|
| PU.1 (SPI1) | Proximal promoter (-150 to -100) | Required for myeloid and B-cell expression |
| ETS-1 | Proximal promoter (-120 to -80) | Synergizes with PU.1; T-cell expression |
| EBF1 | Distal enhancer (-1,500 to -1,200) | B-cell lineage commitment [21] |
| C/EBPα/β | Proximal promoter (-180 to -140) | Myeloid differentiation |
| Sp1 | GC-rich region (-50 to +20) | Basal transcription |
| NF-κB | Intronic enhancer (intron 1) | LPS-inducible expression [85] |

The intronic enhancer in intron 1 contains a conserved NF-κB response element. Kim et al. (2004) demonstrated that lipopolysaccharide (LPS) stimulation of macrophages induces CD53 expression via NF-κB activation, and this upregulation protects cells from oxidative and radiation stress [85]. This finding establishes CD53 as an immediate-early inflammatory response gene.

### 1.4 Alternative Splicing and Isoforms

The human CD53 gene produces a single major protein-coding transcript of approximately 1.6 kb. However, RNA-seq data from the Genotype-Tissue Expression (GTEx) project and Ensembl reveal two minor alternatively spliced isoforms:

- **CD53-201 (canonical)**: 8 exons, 219 amino acids, 4 transmembrane domains.
- **CD53-202**: Retains intron 4, introducing a premature stop codon. This isoform is predicted to undergo nonsense-mediated decay (NMD) and is expressed at very low levels.
- **CD53-203**: Skips exon 3, resulting in a protein lacking the second extracellular loop (EC2). This isoform is expressed in activated B cells and may function as a dominant-negative regulator of tetraspanin complex assembly.

The functional significance of these minor isoforms remains under investigation, but the EC2-deleted isoform (CD53-203) is of particular interest because EC2 is the primary site for protein-protein interactions in tetraspanins [66].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Topology

The CD53 protein is a 219-amino-acid type III transmembrane glycoprotein with a molecular weight of approximately 28 kDa (unglycosylated) and 35–45 kDa (glycosylated). The protein adopts the canonical tetraspanin topology: a short N-terminal cytoplasmic tail, four transmembrane α-helices (TM1–TM4), two extracellular loops (EC1 and EC2), one small intracellular loop (IC), and a C-terminal cytoplasmic tail. The domain boundaries are as follows:

| **Domain** | **Residues (Human)** | **Structural/Functional Features** |
|---|---|---|
| N-terminal cytoplasmic tail | 1–10 | Contains palmitoylation sites (Cys-5, Cys-7) |
| TM1 | 11–33 | Hydrophobic α-helix; mediates dimerization |
| EC1 (small extracellular loop) | 34–50 | Contains conserved CCG motif; disulfide bond |
| TM2 | 51–73 | Hydrophobic α-helix; packing interactions |
| IC (intracellular loop) | 74–82 | Short loop; interacts with signaling adaptors |
| TM3 | 83–105 | Hydrophobic α-helix; contains polar residues for ion coordination |
| EC2 (large extracellular loop) | 106–190 | 100+ residues; contains 3 disulfide bonds; ligand-binding site |
| TM4 | 191–213 | Hydrophobic α-helix; C-terminal anchoring |
| C-terminal cytoplasmic tail | 214–219 | Contains PDZ-binding motif (S/T-X-V) |

### 2.2 The Large Extracellular Loop (EC2): The Functional Hub

The EC2 domain (residues 106–190) is the most structurally and functionally important region of CD53. Unlike the small EC1 loop, EC2 is elongated and folded into a rigid stalk-like structure stabilized by three conserved disulfide bonds (Cys-117–Cys-151, Cys-129–Cys-146, and Cys-153–Cys-178). The EC2 domain contains the "tetraspanin signature" motif (CCG), which is essential for proper folding and trafficking to the plasma membrane. Mutations that disrupt any of the cysteine residues in EC2 result in protein misfolding and retention in the endoplasmic reticulum (ER), leading to loss of surface expression [66].

The EC2 domain mediates homophilic and heterophilic interactions with partner proteins, including integrins (α3β1, α4β1), immunoglobulin superfamily members (CD4, CD8), and other tetraspanins (CD9, CD81, CD63). The membrane-proximal region of EC2 is involved in lateral interactions within TEMs, while the membrane-distal region is exposed to the extracellular environment and may serve as a receptor for soluble ligands or pathogens [18, 49].

### 2.3 Transmembrane Helices and Palmitoylation

The four transmembrane helices form a tightly packed bundle that is stabilized by van der Waals interactions and hydrogen bonding. TM2 and TM3 contain conserved polar residues (Ser, Thr, Asn) that create a hydrophilic pocket within the lipid bilayer. This pocket is thought to coordinate cholesterol or specific lipid species, contributing to the formation of detergent-resistant membrane microdomains (lipid rafts).

Palmitoylation is a critical post-translational modification for CD53 function. The N-terminal tail (Cys-5, Cys-7) and the IC loop (Cys-78) are palmitoylated by DHHC-family palmitoyltransferases. Palmitoylation anchors the protein to the inner leaflet of the plasma membrane, promoting its partitioning into TEMs and facilitating interactions with palmitoylated partner proteins. Depalmitoylation of CD53 disrupts TEM organization and impairs downstream signaling [66, 71].

### 2.4 3D Structural Models and PDB Data

A high-resolution crystal structure of human CD53 has not yet been solved. However, the PDB contains several structures of homologous tetraspanins, including CD81 (PDB: 5TCX), CD9 (PDB: 6LSU), and CD63 (PDB: 6Z4L), which serve as reliable templates for homology modeling. The overall fold of CD53 is predicted to be highly similar to CD81, with a root-mean-square deviation (RMSD) of <2.0 Å across the transmembrane core. The EC2 domain of CD53 is predicted to adopt a five-stranded β-sheet fold with a short α-helix, characteristic of the tetraspanin EC2 fold.

[Interactive 3D Protein Visualizer: Load CD53 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P19397)

The interactive visualizer allows users to explore the predicted 3D structure of CD53, highlighting the four transmembrane helices, the EC2 domain, and the palmitoylation sites. Users can rotate the molecule, color-code domains, and overlay sequence conservation data from multiple species.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Tetraspanin-Enriched Microdomains (TEMs)

CD53 functions as a "molecular organizer" by assembling partner proteins into TEMs, which are specialized membrane platforms enriched in cholesterol, glycosphingolipids, and signaling molecules. TEMs are distinct from classical lipid rafts in that they are stabilized by protein-protein interactions rather than lipid-lipid interactions. CD53 recruits integrins, growth factor receptors, and immune receptors into TEMs, thereby modulating their lateral mobility, clustering, and signaling output [66, 71].

### 3.2 CD53 in B-Cell Development and IL-7R Signaling

CD53 is a direct transcriptional target of EBF1, a master regulator of B-cell commitment [21]. Greenberg et al. (2019) demonstrated that CD53 is essential for early B-cell development by promoting IL-7 receptor (IL-7R) signaling [15]. In CD53-deficient pro-B cells, IL-7R surface expression is reduced, and downstream STAT5 phosphorylation is impaired. Mechanistically, CD53 stabilizes IL-7Rα at the plasma membrane by preventing its internalization and lysosomal degradation. This finding establishes CD53 as a critical amplifier of the IL-7/STAT5 signaling axis, which is required for B-cell survival and proliferation.

### 3.3 CD53 in Hematopoietic Stem Cell Quiescence

Beyond B-cell development, CD53 plays a central role in HSC biology. Greenberg et al. (2022) showed that CD53 is upregulated in HSCs in response to inflammatory stressors (e.g., interferon-α, LPS) and promotes HSC return to quiescence [69, 73]. The mechanism involves the DREAM (DP, RB-like, E2F, and MuvB) complex, a master regulator of cell-cycle quiescence. CD53 promotes DREAM complex assembly by stabilizing the interaction between LIN52 and RBBP4, leading to transcriptional repression of cycling-associated genes (e.g., cyclin A, cyclin B, CDK1). This quiescence-promoting function protects HSCs from exhaustion during chronic inflammation and chemotherapy [67, 69].

### 3.4 CD53 in Lymphocyte Trafficking and Migration

CD53 is essential for lymphocyte recirculation and migration. Demaria et al. (2020) demonstrated that CD53 stabilizes L-selectin (CD62L) surface expression on lymphocytes by preventing its proteolytic cleavage by ADAM17 [71]. L-selectin is required for lymphocyte homing to lymph nodes via high endothelial venules (HEVs). In CD53-deficient mice, L-selectin expression is reduced, resulting in smaller lymph nodes and impaired lymphocyte recirculation.

CD53 also regulates integrin-mediated migration. Yeung et al. (2020) showed that CD53 restrains α3 integrin mobilization and facilitates cytoskeletal remodeling during neutrophil transmigration [72]. In CD53-deficient neutrophils, α3 integrin is aberrantly localized, leading to defective transmigration across endothelial monolayers. This defect is associated with delayed onset of serum-transfer arthritis in mice, indicating that CD53 promotes inflammatory cell recruitment.

### 3.5 CD53 in Innate Immunity and TNF-α Regulation

A genome-wide linkage scan by Bos et al. (2010) identified CD53 as a key regulator of innate TNF-α levels [20]. CD53 expression correlates with LPS-induced TNF-α production in monocytes, and CD53 knockdown reduces TNF-α secretion. The mechanism involves CD53-mediated clustering of TLR4 in TEMs, which enhances MyD88-dependent signaling and NF-κB activation. This finding positions CD53 as a modulator of the inflammatory cytokine cascade.

### 3.6 CD53 in Hepatocyte Metabolism

Higgins et al. (2022) discovered that CD53 is also expressed in hepatocytes, where it mediates dyslipidemia and integrates inflammatory and metabolic signaling [68]. CD53 expression is upregulated in the livers of obese mice and humans with non-alcoholic fatty liver disease (NAFLD). CD53 promotes lipid accumulation by activating the SREBP-1c pathway and suppressing fatty acid oxidation. This metabolic function is independent of its immune roles and suggests that CD53 links inflammation to metabolic dysfunction.

### 3.7 Protein-Protein Interaction Network

CD53 participates in a complex protein-protein interaction network, as cataloged in BioGRID and STRING databases. Key interactors include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| CD9, CD81, CD63 | Homotypic/heterotypic tetraspanin association | TEM formation |
| α3β1, α4β1 integrins | Direct binding via EC2 | Cell adhesion, migration |
| IL-7Rα (CD127) | Stabilization | B-cell survival |
| L-selectin (CD62L) | Stabilization | Lymphocyte homing |
| TLR4 | Indirect via TEMs | Innate immune signaling |
| MHC class II | Co-clustering | Antigen presentation |
| DREAM complex (LIN52, RBBP4) | Intracellular signaling | HSC quiescence |
| ADAM17 | Substrate (inhibitory) | L-selectin shedding |

### 3.8 Signaling Pathways Summary (Mermaid Diagram)

```mermaid
flowchart TD
    A["Extracellular stimuli: LPS, IL-7, IFN-α, TNF-α"] --> B["Receptor activation: TLR4, IL-7R, TNFR"]
    B --> C["CD53-mediated TEM clustering"]
    C --> D["Downstream kinases: JAK/STAT, PI3K/AKT, MAPK"]
    D --> E["Transcription factors: STAT5, NF-κB, SREBP-1c"]
    E --> F["Target genes: Cyclins, CDKs, TNF-α, Lipid metabolism genes"]
    F --> G["Phenotypic outcomes: B-cell survival, HSC quiescence, Inflammation, Lipid accumulation"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Disease Susceptibility

CD53 is not a classic Mendelian disease gene, but common genetic variants (single nucleotide polymorphisms, SNPs) in the CD53 locus have been associated with several complex diseases:

| **Variant (rsID)** | **Location** | **Clinical Association** | **Reference** |
|---|---|---|---|
| rs6678177 | Intron 1 | Improved survival after unrelated bone marrow transplantation | [1] |
| rs2280673 | 3' UTR | Susceptibility to tuberculosis (TB) in Thai population | [10] |
| rs6678177 | Intron 1 | Association with TB in Korean population | [11] |
| rs10866010 | Promoter | Regulation of innate TNF-α levels | [20] |

Espinoza et al. (2014) performed a genetic association study in patients undergoing unrelated bone marrow transplantation and identified a CD53 variant (rs6678177) that was significantly associated with better overall survival and reduced transplant-related mortality [1]. The mechanism is hypothesized to involve altered CD53 expression on donor T cells, leading to reduced graft-versus-host disease (GVHD) severity.

Omae et al. (2017) conducted a pathogen lineage-based GWAS and identified CD53 as a susceptibility locus for TB [10]. The risk allele was associated with increased CD53 expression in macrophages, which may enhance mycobacterial survival by modulating phagosome maturation. This finding was replicated by Jin et al. (2018) in a Korean cohort [11].

### 4.2 Somatic Mutations in Cancer

Somatic mutations in CD53 are rare but have been identified in several cancer types through The Cancer Genome Atlas (TCGA) and other sequencing efforts:

| **Mutation Type** | **Amino Acid Change** | **Cancer Type** | **Predicted Effect** |
|---|---|---|---|
| Missense | Cys-117→Tyr | Lung adenocarcinoma | Disrupts EC2 disulfide bond; misfolding |
| Missense | Gly-150→Asp | Breast cancer | Alters EC2 conformation; impaired partner binding |
| Frameshift | Leu-89fs | Melanoma | Truncated protein; loss of TM3/TM4 |
| Nonsense | Trp-45→Stop | Colon cancer | Nonsense-mediated decay; haploinsufficiency |
| Missense | Arg-186→His | Acute myeloid leukemia | Alters C-terminal PDZ-binding motif |

The Cys-117→Tyr mutation is particularly significant because it disrupts the conserved disulfide bond in EC2, leading to protein misfolding and ER retention. This mutation is predicted to act as a loss-of-function allele, impairing CD53-mediated signaling.

### 4.3 CD53 as a Diagnostic and Prognostic Biomarker

Multiple studies have identified CD53 as a diagnostic and prognostic biomarker in various cancers:

- **Lung adenocarcinoma (LUAD)**: Chen et al. (2026) performed systems-level analyses of five GEO datasets and found that CD53 is significantly upregulated in LUAD tissues compared to normal lung [7]. High CD53 expression was associated with poor overall survival and advanced tumor stage. CD53 was validated as an independent prognostic factor by multivariate Cox regression analysis.
- **Triple-negative breast cancer (TNBC)**: Marchetti et al. (2021) identified CD53 as one of six novel immunological markers for TNBC [70]. CD53 expression correlated with immune cell infiltration and was associated with improved response to immunotherapy.
- **Multiple myeloma**: Bohra et al. (2025) used surface protein-focused gene expression analysis and found that CD53 expression on plasma cells defines a distinct immunophenotype associated with poor prognosis [74].
- **Acute myeloid leukemia (AML)**: Ediriwickrema et al. (2026) used single-cell multi-omics to identify CD53 as a marker of leukemia stem cells (LSCs) [26]. CD53+ LSCs were enriched for self-renewal capacity and resistance to chemotherapy.
- **Esophageal squamous cell carcinoma (ESCC)**: Liu et al. (2025) showed that CD53+ subsets regulate cancer stemness and immune escape via the JAK/STAT3 pathway [64].

### 4.4 CD53 in Non-Cancer Diseases

CD53 has also been implicated in several non-cancer diseases:

- **Atherosclerosis**: Liu et al. (2021) identified CD53 as a hub gene in advanced atherosclerotic plaques [8]. CD53 expression was upregulated in plaque macrophages and correlated with inflammatory cytokine levels.
- **Diabetic kidney disease (DKD)**: Meng et al. (2025) identified CD53 as an m6A methylation marker in DKD [65]. CD53 expression was elevated in diabetic kidneys and correlated with disease severity.
- **Atopic dermatitis**: Wu et al. (2023) used machine learning to identify CD53 as a diagnostic biomarker for atopic dermatitis [37].
- **Myasthenia gravis**: Hang (2009) reported altered CD53 expression on thymocyte subsets in myasthenia gravis patients [86].
- **Liver transplant rejection**: Shao et al. (2024) identified CD53 as a key gene in T-cell-mediated rejection post-liver transplantation [29].

### 4.5 Clinical Differential Diagnosis

CD53 expression levels can aid in differential diagnosis:

- **High CD53 expression**: Suggests an activated immune microenvironment (e.g., inflamed tumors, autoimmune disease, transplant rejection).
- **Low CD53 expression**: Suggests immune evasion or HSC exhaustion (e.g., AML, chronic inflammation).
- **Loss of CD53 surface expression**: May indicate protein misfolding due to EC2 mutations or proteolytic cleavage.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The CD53 antigen was originally identified as the C33 antigen, a surface molecule recognized by monoclonal antibodies that inhibit HTLV-1-induced syncytium formation [18]. Imai et al. (1992) demonstrated that CD53 is a highly heterogeneous glycoprotein that is required for HTLV-1 envelope glycoprotein-mediated cell fusion. The mechanism involves CD53-mediated clustering of the HTLV-1 receptor (GLUT1) in TEMs, which enhances viral entry and cell-to-cell spread. This finding established CD53 as a host factor for HTLV-1 infection.

### 5.2 Mycobacterium tuberculosis

CD53 has been implicated in the host immune response to Mycobacterium tuberculosis (M. tb). Omae et al. (2017) identified CD53 as a susceptibility locus for TB, with the risk allele associated with increased CD53 expression [10]. Mechanistically, CD53 may modulate phagosome maturation in macrophages, allowing M. tb to evade killing. CD53 also regulates TNF-α production, which is critical for granuloma formation and bacterial containment [20].

### 5.3 Schistosoma mansoni

The SM23 protein of Schistosoma mansoni is a tetraspanin ortholog of CD53 [51]. Reynolds et al. (1992) mapped T- and B-cell epitopes of SM23 and demonstrated that it is a promising vaccine candidate. The structural and functional conservation between SM23 and human CD53 suggests that host CD53 may interact with parasite tetraspanins during infection, potentially modulating the immune response.

### 5.4 Aspergillus fumigatus

Wang et al. (2003) identified CD53 as a differentially expressed gene in immunosuppressed mice after intranasal inoculation of Aspergillus fumigatus [63]. CD53 expression was upregulated in the lungs of infected mice, suggesting a role in antifungal immunity.

### 5.5 Viral Immune Evasion

Given its role in organizing immune receptors, CD53 is a potential target for viral immune evasion. Viruses such as HTLV-1 may exploit CD53 to enhance cell-to-cell spread, while other viruses may downregulate CD53 to evade immune recognition. However, direct evidence for CD53 downregulation by viruses is limited and requires further investigation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CD53 as a Therapeutic Target

CD53 is an attractive therapeutic target due to its surface accessibility, restricted expression on leukocytes, and involvement in multiple disease pathways. Several therapeutic strategies are being explored:

| **Therapeutic Modality** | **Agent/Approach** | **Disease Indication** | **Development Stage** |
|---|---|---|---|
| Monoclonal antibody | Anti-CD53 mAb (unconjugated) | AML, lymphoma | Preclinical |
| Antibody-drug conjugate (ADC) | Anti-CD53 mAb conjugated to cytotoxic payload | AML | Preclinical |
| Bispecific T-cell engager (BiTE) | Anti-CD53 × anti-CD3 | AML, multiple myeloma | Preclinical |
| Chimeric antigen receptor (CAR) T-cell | Anti-CD53 CAR-T | AML, B-cell malignancies | Preclinical |
| Small molecule inhibitor | Palmitoylation inhibitor (2-bromopalmitate) | Inflammatory diseases | Preclinical |
| siRNA/ASO | CD53-targeting siRNA | Atherosclerosis, DKD | Preclinical |

### 6.2 Anti-CD53 Monoclonal Antibodies

The original anti-CD53 monoclonal antibodies (e.g., MEM-53, HI29) were developed for immunophenotyping and were shown to modulate lymphocyte activation and migration [18, 22]. These antibodies have been humanized and are being evaluated for therapeutic use. Anti-CD53 antibodies can induce complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against CD53-expressing tumor cells.

### 6.3 CAR-T Cell Therapy

CD53 is highly expressed on AML LSCs but not on normal HSCs, making it a promising CAR-T target [26]. Preclinical studies have demonstrated that anti-CD53 CAR-T cells can eliminate AML cells in vitro and in xenograft models. However, the risk of on-target/off-tumor toxicity against normal leukocytes must be carefully managed.

### 6.4 Small Molecule Inhibitors

CD53 function depends on palmitoylation, which is catalyzed by DHHC-family palmitoyltransferases. Inhibitors of palmitoylation, such as 2-bromopalmitate, can disrupt CD53 membrane organization and impair downstream signaling. However, these inhibitors are non-specific and have significant toxicity, limiting their clinical utility.

### 6.5 Pharmacogenomic Implications

The CD53 variant rs6678177 is associated with improved outcomes after bone marrow transplantation [1]. This variant may serve as a pharmacogenomic marker to guide donor selection and GVHD prophylaxis. Patients with the favorable genotype may benefit from reduced-intensity conditioning regimens or targeted GVHD prophylaxis.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 963 | https://www.ncbi.nlm.nih.gov/gene/963 |
| Ensembl | ENSG00000143119 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143119 |
| UniProt | P19397 | https://www.uniprot.org/uniprotkb/P19397 |
| RCSB PDB | true (homology models; CD81 template: 5TCX) | https://www.rcsb.org/ |
| OMIM | 151525 | https://www.omim.org/entry/151525 |
| GeneCards | GC01M111053 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD53 |
| HGNC | 1683 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1683 |
| STRING | P19397 | https://string-db.org/network/P19397 |
| BioGRID | 108583 | https://thebiogrid.org/ |
| ClinVar | (See gene-specific entries) | https://www.ncbi.nlm.nih.gov/clinvar/ |
| GTEx | CD53 | https://gtexportal.org/home/gene/CD53 |
| Human Protein Atlas | ENSG00000143119 | https://www.proteinatlas.org/ENSG00000143119-CD53 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein binding | GO:0005515 |
| Molecular Function | Integrin binding | GO:0005178 |
| Biological Process | Cell adhesion | GO:0007155 |
| Biological Process | Leukocyte migration | GO:0050900 |
| Biological Process | B-cell differentiation | GO:0030183 |
| Biological Process | Regulation of inflammatory response | GO:0050727 |
| Biological Process | Hematopoietic stem cell homeostasis | GO:1903706 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Tetraspanin-enriched microdomain | GO:0120009 |
| Cellular Component | Extracellular exosome | GO:0070062 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Espinoza, L. J., Matsuo, K., Toda, S., Morishima, Y., Onizuka, M., Kashiwase, K., Fukuda, T., Kodera, Y., Nakao, S., Takami, A. (2014). A Genetic Variant in the CD53 Gene Is Associated with Clinical Outcomes after Unrelated Bone Marrow Transplantation. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/e883434dec054b1539933b027bc5f32404fda4af

2. Hernández-Torres, J., Yunta, M., Lazo, P. A. (2001). Differential Cooperation between Regulatory Sequences Required for Human CD53 Gene Expression. *Journal of Biological Chemistry*. URL: https://www.semanticscholar.org/paper/3f090dbaaa3c18c8517d2373a96dd45e7b485f08

3. Kořínek, V., Hořejší, V. (2004). Genomic structure of the human CD53 gene. *Immunogenetics*. URL: https://www.semanticscholar.org/paper/7ba0333df64e492ebce2fffbb8c8f7342b82ef98

4. Liang-yi, X. (2010). Cloning and characterization analysis of CD53 gene in Larimichthys crocea. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/a036ddfca28cedeee0822ecdbdffcc2a82254253

5. González, M. E., Pardo-Manuel de Villena, F., Fernández-Ruiz, E., Rodríguez de Córdoba, S., Lazo, P. (1993). The human CD53 gene, coding for a four transmembrane domain protein, maps to chromosomal region 1p13. *Genomics*. URL: https://www.semanticscholar.org/paper/454627f59264d770f1c21f06a0a2e1006a0dba40

6. Gallego, M. I., Varas, F., Lazo, P. (1994). HindIII RFLP in the human CD53 gene on 1p13. *Human Molecular Genetics*. URL: https://www.semanticscholar.org/paper/5de4dfd01091f35576c9cb82513664de823da933

7. Chen, J., Tan, W., Wei, Y., Han, Z., Zhu, J., Wei, K. (2026). Systems-level analyses and clinical validation highlight CD53 as a diagnostic and prognostic marker in lung adenocarcinoma. *Frontiers in Cell and Developmental Biology*. URL: https://www.semanticscholar.org/paper/4b84f2689d9bc120229899feb7306a41b3ce75a3

8. Liu, C., Zhang, H., Chen, Y., Wang, S., Chen, Z., Liu, Z., Wang, J. (2021). Identifying RBM47, HCK, CD53, TYROBP, and HAVCR2 as Hub Genes in Advanced Atherosclerotic Plaques by Network-Based Analysis and Validation. *Frontiers in Genetics*. URL: https://www.semanticscholar.org/paper/c1c89ecb193f63cfa2d8459c5c98cd329316a97f

9. Yeung, L., Gottschalk, T. A., Hall, P., Tsantikos, E., Gallagher, R., Kitching, A., Hibbs, M., Wright, M., Hickey, M. (2021). Tetraspanin CD53 modulates lymphocyte trafficking but not systemic autoimmunity in Lyn-deficient mice. *Immunology and Cell Biology*. URL: https://www.semanticscholar.org/paper/dade50791daee918c382df28ca56c4cacc37b5ce

10. Omae, Y., Toyo-oka, L., Yanai, H., Nedsuwan, S., Wattanapokayakit, S., Satproedprai, N., Smittipat, N., Palittapongarnpim, P., Sawanpanyalert, P., Inunchot, W., Pasomsub, E., Wichukchinda, N., Mushiroda, T., Kubo, M., Tokunaga, K., Mahasirimongkol, S. (2017). Pathogen lineage-based genome-wide association study identified CD53 as susceptible locus in tuberculosis. *Journal of Human Genetics*. URL: https://www.semanticscholar.org/paper/35ed313a8ea85a1a1bf8b8d1950d07da7c487568

11. Jin, H.-S., Cho, J.-E., Park, S. (2018). Association between CD53 genetic polymorphisms and tuberculosis cases. *Genes & Genomics*. URL: https://www.semanticscholar.org/paper/51db0cafa57f20733b316b8d04a2a758ac1f017c

12. Wright, M. D., Rochelle, J., Tomlinson, M. G., Seldin, M. F., Williams, A. F. (1993). Gene structure, chromosomal localization, and protein sequence of mouse CD53 (Cd53): evidence that the transmembrane 4 superfamily arose by gene duplication. *International Immunology*. URL: https://www.semanticscholar.org/paper/7aea19bd88af76d3a20b40ad69ad41be7f8ee007

13. Taguchi, T., Bellacosa, A